Clinical Trial: Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

U.S., May 6 -- ClinicalTrials.gov registry received information related to the study (NCT07566494) titled 'Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease' on May 02.

Brief Summary: Background:

Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen. Research has shown that curcumin, a natural compound found in turmeric, can improve the health of red blood cells in people with SCD. But the body cannot absorb curcumin well when it is taken by mouth. Researchers want to know if a skin gel (VAS-101) can help the body better absorb curcumin. VAS-101 contains curcumin, which comes from turmeric.

Objective:

To test VAS-101 in people with stable SCD. ...